REG - GSK PLC - Director/PDMR Shareholding
15/02/2023 16:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230215:nRSO0567Qa&default-theme=true
RNS Number : 0567Q GSK PLC 15 February 2023
GSK plc (the 'Company')
Vesting of Deferred Bonus Awards under the Deferred Annual Bonus Plan and Sale
of Ordinary Shares
This notification sets out the vesting details for Persons Discharging
Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary
Shares made in 2020 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
('DABP') and subsequent sale of Ordinary Shares to meet tax liabilities. In
accordance with the shareholder approved 2017 Remuneration Policy and the DABP
rules, the awards comprised a mandatory bonus deferral only. The three-year
restricted period for the awards commenced on 14 February 2020 and ended on 14
February 2023. Dividends accrued on the awards during the restricted period.
The awards were granted in 2020 as nil-cost options over Ordinary Shares.
The closing price of Ordinary Shares of GSK plc on 14 February 2023 was
£14.70.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 60,707
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8730 28,576
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 40,985
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8887 19,292
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 7,893
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8743 4,240
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 11,259
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8628 5,305
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 4,796
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8804 2,263
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 18,375
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8830 1,171
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 13,471
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8750 6,348
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 9,539
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8756 4,500
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of an award in the form of a nil-cost option over Ordinary Shares
granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the
subsequent exercise of the nil-cost option
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 7,779
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the exercise of a
nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8772 3,669
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-14
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFFFMIEDSESERecent news on GSK
See all newsREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - 1st Quarter Results
AnnouncementREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
Announcement